CagriSema
Also known as: Cagrilintide + semaglutide, NN9838 + semaglutide
CagriSema (also called Cagrilintide + semaglutide or NN9838 + semaglutide) is a research peptide in the GLP-1 Agonist class. CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GLP-1 receptorAmylin receptor
Vendor price snapshot
Price per mg is list price divided by vial size in milligrams when both are known from public vendor listings. Peptide Library does not sell peptides. Confirm live prices on the vendor site.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg range
- $22.00/mg
Research summary
Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.
Peptide Library's CagriSema profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Weekly fixed-dose combinations in REDEFINE trials
- Frequency
- Once weekly
- Cycle
- Long-term trial setting
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. CagriSema is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection. The two act on separate satiety pathways: amylin signalling operates through amylin and calcitonin receptor complexes in the area postrema, while GLP-1 acts on its own receptors in the hypothalamus and brainstem. Because the pathways converge on food intake without sharing a receptor, the combination is intended to produce greater appetite suppression than either alone, and it is being studied to determine whether that translates into additive weight reduction.
Origin
Investigational combination of two peptides.
Targets
Studies
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
Regulatory & research status
CagriSema has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Potential Side Effects
Side Effects
- Nausea
- Constipation
- GI class effects
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
CagriSema: frequently asked questions
What is CagriSema?
Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.
How does CagriSema work?
CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection. The two act on separate satiety pathways: amylin signalling operates through amylin and calcitonin receptor complexes in the area postrema, while GLP-1 acts on its own receptors in the hypothalamus and brainstem.
Is CagriSema FDA approved?
No. CagriSema is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
Is CagriSema banned in sport?
CagriSema is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to CagriSema?
Compounds most often compared with CagriSema include Cagrilintide, Pramlintide, Petrelintide and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 — Hypertension, 2026External reference
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study — Lancet Diabetes Endocrinol, 2026External reference
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study — Lancet Diabetes Endocrinol, 2026External reference
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — N Engl J Med, 2025External reference
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis — BMJ, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This CagriSema profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track CagriSema research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →